EQL Pharma - Sales record in the third quarter
CEO’s comments The third quarter of fiscal year 2019/20 was a strong quarter for EQL with growth of 83 percent and sales of SEK 20.1 (11.4) million. It is thus EQL Pharma's best quarter ever from a sales perspective and the second quarter in a row we set sales records. Profitability was good with an EBITDA of SEK 2.6 (0.0) million, corresponding to an operating margin of 13 percent.During the quarter, EQL Pharma launched Methenamine hippurate, the only generic besides the original. The product is important, among other things, as a prophylaxis against recurrent urinary tract